April 2023

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity perspectives across metabolic and obesity care – 430

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity: perspectives across metabolic and obesity care – 4/30

AT A GLANCE… At the Fortune Brainstorm Health conference, I put Chelsea Clinton on the spot for her suggestions to manage the looming four billion people across the globe who will be living with obesity by the year 2035. In The Atlantic, Yasmin Tayag leads with ‘We’ve had a cheaper, more potent Ozempic alternative for decades…’ on bariatric surgery ‘…to be the […]

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity: perspectives across metabolic and obesity care – 4/30 Read More »

Ongoing obsession with GLP-1 drugs, bariatric surgery improves lives for adolescents and those with liver disease, and more: perspectives across metabolic and obesity care – 4/23

AT A GLANCE… GLP-1 drugs continue to hit the headlines, with United Health Group CEO Andrew Witty weighing in on their benefit and usage. Pregnancy risks of GLP-1 meds – very low likelihood, though currently unknown beyond animal studies. Teledoc strides into GLP-1 space; and Ro founder Zachariah Reitano publishes a long piece on the scientific basis of obesity management with respect to

Ongoing obsession with GLP-1 drugs, bariatric surgery improves lives for adolescents and those with liver disease, and more: perspectives across metabolic and obesity care – 4/23 Read More »

Fast growth, even faster pivots in the GLP-1 space Perspectives across metabolic and obesity care – 416

Fast growth, even faster pivots in the GLP-1 space? Perspectives across metabolic and obesity care – 4/16

AT A GLANCE… Calibrate, a telehealth GLP-1 prescription machine, reports an 18% reduction in workforce, with a move to employer-based contracts. Legacy weight loss companies focused upon behavior change, counting calories and low-carb diets are in a quandary whether to embrace anti-obesity medications. Prediabetes currently affects 1 in 3 adult Americans and is projected to impact over one billion people across

Fast growth, even faster pivots in the GLP-1 space? Perspectives across metabolic and obesity care – 4/16 Read More »

Beyond BMI, military struggles with obesity, and more: perspectives across metabolic and obesity care – 4/9

I wish everyone a Happy Easter if you celebrate and happy weekend if you do not 🙂 AT A GLANCE… Beyond BMI – a high-profile academic committee gets together this week to debate and define the role of BMI as a measure of obesity and health. The U.S. military is struggling with recruitment and lost workdays of their soldiers due to

Beyond BMI, military struggles with obesity, and more: perspectives across metabolic and obesity care – 4/9 Read More »

WHO, GLP-1s and more perspectives across metabolic and obesity care – 42

WHO, GLP-1s and more: perspectives across metabolic and obesity care – 4/2

AT A GLANCE… New data on Rybelsus oral GLP-1 medication from Novo Nordisk, in addition to newbie GLP-1/GIP medication [akin to Mounjaro from Eli Lilly] from Viking Therapeutics, code-named VK2735. The anti-obesity medication market is hotting up, with aligned stock price increases across the board. Are anti-obesity medications the next frontier in saving millions of lives across the globe,

WHO, GLP-1s and more: perspectives across metabolic and obesity care – 4/2 Read More »

Scroll to Top
Skip to content